Medication for Sleep (Insomnia)
For adults with uncomplicated chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) should be first-line treatment, but when pharmacotherapy is needed, eszopiclone, zolpidem, or the dual orexin receptor antagonists (DORAs: suvorexant, lemborexant, daridorexant) are the most evidence-based options, with DORAs offering advantages of no withdrawal, rebound insomnia, or abuse potential 1, 2.
Treatment Algorithm
First-Line: Non-Pharmacologic
- CBT-I is mandatory first-line treatment before considering medications for chronic insomnia 2, 3, 4
- This applies to all ages, including older adults and those with comorbidities
- Can be delivered in-person or digitally with equal efficacy
When Pharmacotherapy is Indicated
If CBT-I fails, is unavailable, or for short-term use:
Best Evidence-Based Options (in order of preference):
1. Dual Orexin Receptor Antagonists (DORAs) - Preferred for longer-term use
- Daridorexant, lemborexant, or suvorexant 5, 2
- Mechanism: Inhibit wakefulness rather than induce sedation
- Key advantages: No rebound insomnia, no withdrawal symptoms, minimal abuse potential 5
- Approved for up to 3 months or longer 2
- Daridorexant has ideal 8-hour half-life and demonstrated 12-month efficacy 5
2. Nonbenzodiazepine Benzodiazepine Receptor Agonists (Z-drugs)
- Eszopiclone or zolpidem 1
- Moderate-quality evidence for short-term efficacy
- Effect sizes are small but statistically significant 1
- Critical caveat: FDA mandates warning about "sleep-related complex behaviors" including sleep-driving 6
- Dose reduction required for women due to morning carryover effects with zolpidem 6
- Recommended for ≤4 weeks 2
3. Low-Dose Doxepin (tricyclic antidepressant)
- Particularly useful in older adults (>65 years) 7, 4
- FDA-approved specifically for insomnia at low doses
- Can be used short-term (≤4 weeks) or longer with careful monitoring 2
4. Melatonin Receptor Agonists
- Ramelteon for general adults 5, 4
- Prolonged-release melatonin specifically for patients ≥55 years, up to 3 months 2
- Particularly useful in older adults 7
Duration Considerations:
- Short-term (≤4 weeks): Benzodiazepines, Z-drugs, low-dose doxepin 2
- Longer-term (3+ months): DORAs preferred; others may be continued weighing risks/benefits 2
- Important: Since 2005, FDA has approved hypnotics without duration restrictions, recognizing chronic insomnia often lasts >2 years 6
What NOT to Use
Strong recommendations AGAINST 2, 3:
- Antihistamines (e.g., diphenhydramine, doxylamine)
- Antipsychotics
- Fast-release melatonin
- Phytotherapeutics/herbal supplements
- Complementary/alternative treatments (homeopathy, acupuncture)
Critical Safety Considerations
Serious Harms from Observational Data:
- Increased risk of dementia, fractures, and major injury with chronic hypnotic use 1
- Cognitive and behavioral changes including driving impairment 1
- Dose reductions advised for women and older adults by FDA 1
Age-Specific Concerns:
- Older adults (>65): Risks increase with age; prefer low-dose doxepin, melatonin, ramelteon, or DORAs 7
- Avoid benzodiazepines in elderly due to fall risk and cognitive impairment
Evidence Quality Context
The 2016 American College of Physicians guideline 1 provides the strongest evidence base, noting:
- Only eszopiclone, zolpidem, and suvorexant have moderate-quality evidence
- Effect sizes are small even for approved medications
- Most trials were short-term with stringent enrollment criteria
- Comparative effectiveness data is lacking - we cannot definitively say which medication is superior
- Long-term efficacy remains unknown for most agents
The 2023 European Insomnia Guideline 2 updates this with stronger recommendations for DORAs based on newer evidence, representing the most current consensus.
Selection Strategy
Choose based on:
- Sleep pattern: DORAs work throughout the night; short-acting Z-drugs for sleep-onset only
- Age: DORAs or low-dose doxepin for older adults
- Duration needed: DORAs for longer-term; Z-drugs for short-term
- Comorbidities: Consider drug interactions and contraindications
- Patient preference regarding mechanism (sedation vs. wake inhibition)
Set clear expectations: Pharmacotherapy provides modest improvements and should ideally be time-limited with ongoing monitoring 4.